摘要
目的研究联合检测血红素加氧酶1(HO-1)和鳞状细胞癌抗原(SCC)对食管癌的诊断价值及对放化疗疗效的影响。方法选取我院2015年2月至2016年2月收治的100例行放化疗治疗的食管癌患者(研究组),同期我院体检的26例健康者(对照组)。两组均在入院时及化疗后采集静脉血并用酶联免疫吸附法进行血清HO-1、SCC检测。观察不同临床分期、病理分级食管癌患者血清HO-1、SCC表达,比较放化疗前后血清HO-1、SCC浓度变化。结果研究组血清HO-1、SCC表达随临床分期升高而增加,血清HO-1随分化程度降低而减少,血清SCC表达随分化程度降低而增加(P<0.05)。ROC曲线分析,在食管癌诊断方面血清HO-1、SCC联合检测敏感性与曲线下面积(AUC)均高于单独检测;研究组放化疗后血清HO-1、血清SCC表达均低于放化疗前(P<0.05);研究组放化疗前后血清HO-1、SCC表达均高于对照组(P<0.05)。结论食管癌患者血清HO-1、SCC在不同临床分期、病理分级之间表达存在一定差异,联合检测可为临床检测食管癌发生、发展提供新依据;通过研究食管癌患者放化疗前后血清HO-1、SCC表达改变,能为临床评估放化疗疗效及预后提供重要参考依据。
Objective To explore the diagnostic value and effect on chemoradiotherapy （CRT） of joint detection of heme oxy- genase 1 （ HO-1 ） and squamous cell carcinoma Ag （SCC-Ag） in patients with esophageal cancer. Methods One hundred patients with esophageal cancer patients undergoing CRT in our hospital from February 2015 to February 2016 were selected as rescarch group. Meanwhile,26 healthy controls in our hospital were randomly selected as control group. When patients entered into hospital and after chemotherapy, the blood samples were taken, and serum HO-1 and SCC were detected by enzyme linked immunosorbent assays. The ser- um HO-1 and SCC-Ag levels in different clinical stages and pathological grading in the patients were observed. The changes of HO-1 and SCC-Ag concentration before and after CRT were compared. Results The serum HO-1 and SCC levels in the research group were increased as clinical stages elevated （ P 〈 0. 05 ）. The serum HO-1 in the research group was decreased as differentiation degree re- duced, and serum SCC-Ag was increased as differentiation degree reduced （P 〈 0. 05 ）. ROC curve analysis showed that serum HO-1 and SCC-Ag had certain application value in diagnosis of esophageal cancer, and the sensitivity and specificity of the joint detection were higher than single marker detection. After CRT, the serum HO-1 and SCC-Ag levels in the research group was lower than before CRT （P 〈 0. 05 ）. Moreover, after CRT,the serum HO-1 and SCC-Ag levels in the research group was still higher than those in the con- trol group （P 〈 0. 05）. Conclusion The serum HO-1 and SCC-Ag in esophageal cancer patients have certain difference in different clinical stages and pathological grading. The joint detection of the two markers can provide new basis for clinical detection of occurrence and development of esophageal cancer. The changes of serum HO-1 and SCC-Ag in esophageal cancer patients before and after CRT can provide important reference to clinical evaluation of CRT efficacy a
出处
《实用医院临床杂志》
2017年第5期74-77,共4页
Practical Journal of Clinical Medicine
关键词
联合检测
HO-1
SCC
食管癌
诊断价值
放化疗
Joint detection
HO-1
SCC-Ag
Esophageal cancer
Diagnostic value
Chemoradiotherapy
